Changing antipsychotic medication: Guidelines on the transition to treatment with risperidone

Clinical Therapeutics

Volumn 18, Issue 4, 1996, Pages 592-607

  Borison, Richard L ^a,b   Romano, Steven ^c   Daniel, David G ^c   Davidson, Joyce ^c   DeVane, C Lindsay ^c   Hansen, Mary Susan ^c   Home, Robert ^c   Miller, Del ^c   Remington, Gary ^d  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b Clinical Therapeutics   (United States)

^c NONE   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; CHLORPROMAZINE; CLOZAPINE; DIAZEPAM; LITHIUM; NEUROLEPTIC AGENT; PROCYCLIDINE; RISPERIDONE; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; ZUCLOPENTHIXOL DECANOATE;

AGITATION; ANXIETY; ARTICLE; DRUG WITHDRAWAL; DYSKINESIA; HUMAN; INSOMNIA; MENTAL DISEASE; NAUSEA; PRACTICE GUIDELINE; PSYCHOSIS; REBOUND; SUPERSENSITIVITY; VOMITING; WITHDRAWAL SYNDROME;

EID: 0029745168     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(96)80211-6     Document Type: Article

References (42)

1. Verghese C, De Leon J, Nair C, Simpson GM. Clozapine withdrawal effects and receptor profiles of typical and atypical neuroleptics. Biol Psychiatry. 1996;39: 135-138.
2. Dilsaver SC. Withdrawal phenomena associated with antidepressant and antipsychotic agents. Drug Saf. 1994;10:103-114.
3. Dilsaver SC, Coffman JA. Antipsychotic withdrawal phenomena in the medical-surgical setting. Gen Hosp Psychiatry. 1988;10:438-446.
4. Lieberman J. Cholinergic rebound in neuroleptic withdrawal syndromes. Psychosomatics. 1981;22:253-254.
5. Battegay R. Drug dependence as a criterion for differentiation of psychotropic drugs. Compr Psychiatry. 1966;7:501-509.
6. Chouinard G, Bradwejn J, Annable L, et al. Withdrawal symptoms after long-term treatment with low-potency neuroleptics. J Clin Psychiatry. 1984;45:500-502.
7. Luchins DJ, Freed WJ, Wyatt RJ. The role of cholinergic supersensitivity in the medical symptoms associated with withdrawal of antipsychotic drugs. Am J Psychiatry. 1980;137:1395-1398.
8. Chouinard G, Jones BD, Annable L. Neuroleptic-induced supersensitivity psychosis. Am J Psychiatry. 1978;135: 1409-1410.
9. Chouinard G, Jones BD. Neuroleptic-induced supersensitivity psychosis: Clinical and pharmacologic characteristics. Am J Psychiatry. 1980;137:16-23.
10. Hunt JI, Singh H, Simpson GM. Neuroleptic-induced supersensitivity psychosis: Retrospective study of schizophrenic inpatients. J Clin Psychiatry. 1988;49:258-261.
11. Kahne GJ. Rebound psychosis following discontinuation of a high-potency neuroleptic. Can J Psychiatry. 1989;34: 227-229.
12. Dixon L, Thaker G, Conley R, et al. Changes in psychopathology and dyskinesia after neuroleptic withdrawal in a double-blind design. Schizophr Res. 1993; 10:267-271.
13. Gardos G, Cole JO, Tarsy D. Withdrawal syndromes associated with antipsychotic drugs. Am J Psychiatry. 1978;135: 1321-1324.
14. Nelli AC, Yarden PE, Guazelli M, Feinberg I. Parkinsonism following neuroleptic withdrawal. Arch Gen Psychiatry. 1989;46:383-384. Letter.
15. Lang AE. Withdrawal akathisia: Case report and a proposed classification of chronic akathisia. Mov Disord. 1994;9: 188-192.
16. Maisami M, Golant D. Neuroleptic withdrawal. J Am Acad Child Adolesc Psychiatry. 1991;30:336. Letter.
17. Thaker GK, Wagman AM, Kirkpatrick B, Tamminga CA. Alterations in sleep polygraphy after neuroleptic withdrawal: A putative supersensitive dopaminergic mechanism. Biol Psychiatry. 1989;25:75-86.
18. Lieberman JA, Kane JM, Johns CA. Clozapine: Guidelines for clinical management. J Clin Psychiatry. 1989;50: 329-338.
19. De Leon J, Stanilla JK, White AO, Simpson GM. Anticholinergics to treat clozapine withdrawal. J Clin Psychiatry. 1994; 55:119-120.
20. Simpson GM, Varga E. Clozapine - a new antipsychotic agent. Curr Ther Res. 1974;16:679-686.
21. Simpson GM, Lee JH, Shrivastata RK. Clozapine in tardive dyskinesia. Psychopharmacology. 1978;56:75-80.
22. Ekblom B, Eriksson K, Lindström LH. Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal. Psychopharmacology. 1984; 83:293-294.
23. Eklund K. Supersensitivity and clozapine withdrawal. Psychopharmacology. 1987; 91:135. Letter.
24. Perényi A, Kuncz E, Bagdy G. Early relapse after sudden withdrawal or dose reduction of clozapine. Psychopharmacology. 1985;86:244. Letter.
25. Dilsaver SC, Greden JF. Antidepressant withdrawal phenomena. Biol Psychiatry. 1984;19:237-256.
26. Coward DM, Imperato A, Urwyler S, White TG. Biochemical and behavioral properties of clozapine. Psychopharmacology. 1989;99:S6-S12.
27. Borison RL, Diamond BI, Sinha D, et al. Clozapine withdrawal rebound psychosis. Psychopharmacol Bull. 1988;24:260-263.
28. Parsa MA, al-Lahham YH, Ramirez LF, Meltzer HY. Prolonged psychotic relapse after abrupt clozapine withdrawal. J Clin Psychopharmacol. 1993;13:154-155. Letter.
29. Alphs LD, Lee HS. Comparison of withdrawal of typical and atypical antipsychotic drugs: A case study. J Clin Psychiatry. 1991;52:346-348.
30. Ichikawa J, Meltzer HY. Differential effects of repeated treatment with haloperidol and clozapine on dopamine release and metabolism in the striatum and the nucleus accumbens. J Pharmacol Exp Ther. 1991;256:348-357.
31. Bondolfi G, Baumann P, Patris M, et al. A randomized double-blind study of risperidone versus clozapine for treatment resistant chronic schizophrenia. New Research Program and Abstracts. American Psychiatric Association 148th Annual Meeting; May 20-25, 1995; Miami, Fla; Abstract NR483, p. 185.
32. Wirshing WC, Ames D, Bray MP, et al. Risperidone versus haloperidol in treatment refractory schizophrenic patients: Preliminary results. New Research Program and Abstracts. American Psychiatric Association 148th Annual Meeting; May 20-25, 1995; Miami, Fla; Abstract NR359, p. 152.
33. Chouinard G, Annable L, Ross-Chouinard A, Holobow N. Factors affecting the course of tardive dyskinesia: A 10-year follow-up. In: Syllabus and proceedings of the 143rd annual meeting of the American Psychiatric Association; May 12-17, 1990; New York, New York; Abstract, p. 62.
34. Chouinard G. Effects of risperidone in tardive dyskinesia: An analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol. 1995;15(Suppl 1):36S-44S.
35. Borison RL, Pathiraja AP, Diamond BI, Meibach RC. Risperidone: Clinical safety and efficacy in schizophrenia. Psychopharmacol Bull. 1992;28:213-218.
36. Khan BU, Glazer WM. Risperidone for severely disturbed behavior and tardive dyskinesia in developmentally disabled adults. New Research Poster. American Psychiatric Association 149th Annual Meeting; May 4-9, 1996; New York, NY.
37. Clozaril®. In: Physicians' Desk Reference®. 50th ed. Montvale, NJ: Medical Economics; 1996:2252-2255.
38. Risperdal®. In: Physicians' Desk Reference®. 50th ed. Montvale, NJ: Medical Economics; 1996:1301-1305.
39. Stanley M, Mann JJ. Increased serotonin-2 binding sites in frontal cortex of suicide victims. Lancet. 1983;1:214-216.
40. Bennie EH. High-dose antipsychotic medication. Br J Psychiatry. 1994;165:553. Letter.
41. Zimbroff DL. Switching patients from clozapine to risperidone. Am J Psychiatry. 1995;152:1102. Letter.
42. Seth R, Risperidone Switching Study Investigators. The effects of switching treatment to risperidone: A multi-centre study to test switching strategies. Presented at the Winter Meeting, Royal College of Psychiatrists; January 1995; London, United Kingdom.